- Home
- SABS vs BRTX Comparison
SABS vs BRTX Comparison
Compare SABS & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- BRTX
- Stock Information
- Founded
- SABS 2014
- BRTX 1997
- Country
- SABS United States
- BRTX United States
- Employees
- SABS N/A
- BRTX N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- BRTX Managed Health Care
- Sector
- SABS Health Care
- BRTX Health Care
- Exchange
- SABS Nasdaq
- BRTX Nasdaq
- Market Cap
- SABS 15.8M
- BRTX 12.8M
- IPO Year
- SABS N/A
- BRTX N/A
- Fundamental
- Price
- SABS $2.35
- BRTX N/A
- Analyst Decision
- SABS Strong Buy
- BRTX
- Analyst Count
- SABS 4
- BRTX 0
- Target Price
- SABS $9.50
- BRTX N/A
- AVG Volume (30 Days)
- SABS 427.8K
- BRTX 74.0K
- Earning Date
- SABS 11-05-2025
- BRTX 11-11-2025
- Dividend Yield
- SABS N/A
- BRTX N/A
- EPS Growth
- SABS N/A
- BRTX N/A
- EPS
- SABS N/A
- BRTX N/A
- Revenue
- SABS $114,698.00
- BRTX $605,200.00
- Revenue This Year
- SABS N/A
- BRTX $232.67
- Revenue Next Year
- SABS N/A
- BRTX $52.92
- P/E Ratio
- SABS N/A
- BRTX N/A
- Revenue Growth
- SABS N/A
- BRTX 247.62
- 52 Week Low
- SABS $1.00
- BRTX $1.19
- 52 Week High
- SABS $6.60
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- SABS 54.67
- BRTX 56.08
- Support Level
- SABS $2.20
- BRTX $1.56
- Resistance Level
- SABS $2.60
- BRTX $1.73
- Average True Range (ATR)
- SABS 0.19
- BRTX 0.11
- MACD
- SABS 0.02
- BRTX 0.02
- Stochastic Oscillator
- SABS 68.00
- BRTX 75.93
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.